DiaMedica Therapeutics Inc.
DMACNext catalyst
Recombinant human tissue kallikrein
Acute Stroke
Get an email about DMAC's next catalysts
Track DiaMedica Therapeutics (DMAC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
DMAC Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd
Recombinant human tissue kallikrein Phase 3 Est. Readout (ReMEDy2)
Primary completion for Recombinant human tissue kallikrein trial (NCT05065216) in Acute Stroke
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Recombinant human tissue kallikrein | Phase 3 | Acute Stroke | - | - |
DM199 | Phase 2 | Kidney Diseases | - | - |
Frequently asked questions
What is in DiaMedica Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in DiaMedica Therapeutics Inc.'s (DMAC) pipeline across Phase 3, Phase 2. Its lead program is Recombinant human tissue kallikrein (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is DiaMedica Therapeutics Inc.'s next FDA catalyst?→
DiaMedica Therapeutics Inc.'s (DMAC) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DMAC biotech catalysts?→
Add DMAC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow DiaMedica Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.